Report Overview

Indian Head & Neck Cancer market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Head and neck cancers in India accounted for 30% of all cancers. In India, 60 to 80% of patients present with advanced disease as compared to 40% in developed countries. A slow decline in the incidence of most of head and neck cancers has been documented in India. In India, it accounts for one fourth of male cancers and one tenth of female cancers. This is mainly attributed to tobacco, areca nut, alcohol, etc. Oral cancers are most common amongst all head and neck squamous cell cancers (HNSCC). HNSCC in the developing world differ from those in the Western world in terms of age, site of disease, etiology, and molecular biology. Poverty, illiteracy, advanced stage at presentation, lack of access to health care, and poor treatment infrastructure pose a major challenge in management of these cancers. The increase in the number of risk factors such as the increase in the number of cigarette smoking, alcohol & tobacco use is also poised to drive the growth of the Indian market demand for head & neck cancer drugs.



Market Drivers

The market size drivers for the growth of Head & Neck cancer diagnostics are expected to propel by factors such as growing geriatric population, huge research funding in oncology, unmet medical needs, rising competition among market players, improving regulatory framework, aging population, increase in prevalence of head & neck cancer in India, rise in demand for combination therapy for management of head & neck cancer, and growth in number of R&D activities to develop ideal therapeutic drive the growth of the global head & neck cancer drugs market.